Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cyclerion Therapeutics (CYCN) Change in Account Payables (2019 - 2025)

Historic Change in Account Payables for Cyclerion Therapeutics (CYCN) over the last 7 years, with Q3 2025 value amounting to $18000.0.

  • Cyclerion Therapeutics' Change in Account Payables rose 1250.0% to $18000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $176000.0, marking a year-over-year increase of 22054.79%. This contributed to the annual value of -$445000.0 for FY2024, which is 7488.71% up from last year.
  • Per Cyclerion Therapeutics' latest filing, its Change in Account Payables stood at $18000.0 for Q3 2025, which was up 1250.0% from -$21000.0 recorded in Q2 2025.
  • Cyclerion Therapeutics' Change in Account Payables' 5-year high stood at $1.3 million during Q4 2022, with a 5-year trough of -$2.1 million in Q2 2023.
  • For the 5-year period, Cyclerion Therapeutics' Change in Account Payables averaged around -$18000.0, with its median value being $18000.0 (2025).
  • In the last 5 years, Cyclerion Therapeutics' Change in Account Payables soared by 56618.36% in 2021 and then plummeted by 93104.84% in 2023.
  • Cyclerion Therapeutics' Change in Account Payables (Quarter) stood at $965000.0 in 2021, then skyrocketed by 37.31% to $1.3 million in 2022, then plummeted by 70.94% to $385000.0 in 2023, then tumbled by 77.66% to $86000.0 in 2024, then plummeted by 79.07% to $18000.0 in 2025.
  • Its Change in Account Payables stands at $18000.0 for Q3 2025, versus -$21000.0 for Q2 2025 and $93000.0 for Q1 2025.